Summary
The Department of Drugs of the Swedish National Board of Health and Welfare undertook a study of the possibilities of a new scheme for post-marketing surveillance by means of prescription and register based epidemiological studies, primarily of combined oral contraceptives (COC). Based on available data on COC usage patterns and incidence rates of the disease at study, it was estimated that study periods, including the necessary time periods for disease development and generation of a sufficient number of cases, would amount to at least 1 to 13 years for cardiovascular outcomes and 8 to 17 years for reproductive cancers. Prospective and unbiased exposure ascertainment would be the most important advantage. However, delay in follow up, the need for extensive individual questionnaire probing and fear of violation of personal integrity could adversely affect the feasibility of the scheme. Chiefly on the grounds of the extended study periods and magnitude of the necessary infrastructure, it was not judged cost-effective to pursue such a scheme for COC exposure only. It was, however, suggested that it would be considered for epidemiological surveillance of other drugs that are commonly used and for which short term and frequent serious side effects are expected, as for instance lipid lowering compounds, beta-blockers, bensodiazepines and other psychotropic drugs.
Similar content being viewed by others
References
Moir D (1981) Drug monitoring. Br Med J 282: 632–634
Westerholm B (1987) The rational for a post-marketing surveillance. Hum Reprod 2: 41–44
Report E (1982) Women and children — interviews with women about family and work. Official Statistics of Sweden. National Bureau uf Statistics, Stockholm, pp 38–41
Mishell DR Jr (1989) Contraception. N Engl J Med 320: 777–787
Editorial (1989) Cancer risk of oral contraception. Lancet I: 21–22
Guidelines for the toxicological and clinical assessment and post-registration surveillance of steroidal contraceptive drugs (1987) WHO Special Programme of Research, Development Reseand arch Training in Human Reproduction, WHO Geneva
Knopp RH (1986) Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 31: 913–921
Stadel BV (1981) Oral contraceptives and cardiovascular disease. N Engl J Med 612–618
Stadel BV (1981) Oral contraceptives and cardiovascular disease. N Engl J Med 672–677
Meirik O, Lund E, Adami H-O, Bergström R, Christoffersen T, Bergsjö P (1986) Oral contraceptive use and breast cancer in young women. Lancet II: 650–654
The CASH study (1983) Oral contraceptive use and risk of endometrial cancer. JAMA 249: 1600–1604
The CASH study (1983) Oral contraceptive use and the risk of ovarian cancer. JAMA 249: 1596–1599
Forman D, Vincent TJ, Doll R (1986) Cancer of the liver and the use of oral contraceptives. Br Med J 292: 1357–1361
The In-Patient Registry, National Board of Health and Welfare (1972), Spri Report 18/72, Stockholm, Sweden
The Swedish Cancer Registry, Cancer Incidence in Sweden, (1984) National Board of Health and Welfare, Stockholm, Sweden
The Causes of Death Registry (1986) National Bureau of Statistics, Stockholm, Sweden
The Royal College of General Practitioners' Oral Contraception Study (1978) Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 28: 393–399
Vessey M, Doll R, Peto R, Johnson B, Wiggins P (1976) A long-term follow-up study of women using different methods of contraception — an interim report. J Biosoc Sci 8: 373–427
Casagrande JT, Pike MC, Smith PG (1978) An improved approximate formula for calculating sample sizes forcomparing two binomial distributions. Biometrics 34: 483–6
Skegg DCG (1988) Reviews and Commentary. Potential for bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 127: 205–212
Persson I, Adami H-O, Johansson E, Lindberg B, Manell P, Westerholm B (1983) A cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur J Clin Pharmacol 25: 625–632
Oral contraceptives and health (1974) The RCGP Study. ISBN 0272 793426
Author information
Authors and Affiliations
Additional information
Supported by grants from the National Board of Health and Welfare, Department of Drugs and National Corporation of Pharmacies, Sweden
Rights and permissions
About this article
Cite this article
Persson, I., Adami, H.O., Norell, S.E. et al. Evaluation of a prescription based record-linkage model for epidemiological studies of long-term adverse effects of drugs — with special regard to combined oral contraceptives. Eur J Clin Pharmacol 40, 489–493 (1991). https://doi.org/10.1007/BF00315228
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315228